Australasian Cerebral Palsy Clinical Trials Network (AusCP-CTN): Optimising Interventions And Effective Services For Children With Cerebral Palsy
Funder
National Health and Medical Research Council
Funding Amount
$2,499,287.00
Summary
Cerebral Palsy (CP) is common and disability can be progressive so the heathcare burden is immense (0.14% GDP). Our Clinical trials network will improve early detection and develop new interventions to improve physical, cognitive and health outcomes for children with CP and their families. Recruitment from the national CP Register will address clinically important questions and test implementation of effective treatments. New Clinical Practice Guidelines will ensure translation internationally.
A Randomised Controlled Trial Of Alternative Treatments To Intramuscular Penicillin For Impetigo In Aboriginal Children
Funder
National Health and Medical Research Council
Funding Amount
$1,326,182.00
Summary
We will conduct clinical trials to find an effective, simple and cheap oral alternative to injected penicillin for skin sores which could become the universal standard of care whether the patient is in Melbourne or Milingimbi. It would also likely be adopted by the World Health Organization as a standard of care for developing countries. This would lead directly to a reduced burden of skin sores and their complications. It would also open the way for studies to explore even simpler regimens.
National Centre Of Research Excellence To Improve Management Of Peripheral Arterial Disease
Funder
National Health and Medical Research Council
Funding Amount
$2,618,637.00
Summary
Approximately 15% of adults have blockages or weakness of major arteries in the periphery, associated with impaired quality of life and a high mortality. Significant management deficiencies for these problems include limited diagnostic, prognostic and treatment options, as well as poor adoption of evidence based practice. The proposed national centre will bring together a group of experts in the field to instigate a number of initiatives to improve patient management.
A Phase III Trial Comparing Adjuvant Versus Salvage Radiotherapy For High Risk Patients Post Radical Prostatectomy
Funder
National Health and Medical Research Council
Funding Amount
$819,138.00
Summary
About half of all patients Treated with an operation to remove their prostate cancer have a high chance of the cancer coming back. Giving immediate radiotherapy to all patients will improve cure rates but does not benefit all men and can cause significant side effects. This study explores whether it is safe to wait and only give radiotherapy when there is a rising PSA after surgery indicating active cancer. A total of 470 men from Australasia will enter this study comparing the two approaches.
Aspirin For The Prevention Of Cognitive Decline In The Elderly: A Neuro-Vascular Imaging Study (ENVIS-ion) From ASPREE
Funder
National Health and Medical Research Council
Funding Amount
$1,341,232.00
Summary
The ENVIS-ion trial will examine whether Aspirin is effective in delaying the onset of worsening of thinking and memory abilities in healthy older adults. Magnetic resonance imaging (MRI) of brain structure will detect markers of early worsening of thinking and memory abilities. Blood vessels in the back of the eye (retina) share many features with vessels in the brain. We will compare whether aspirin lessens changes over time of features shown with brain MRI and retinal photography.
An Australasian, Multi-centre, Randomized, Double-blind, Placebo-controlled Trial Of The Efficacy Of Fluoxetine In Improving Functional Recovery After Acute Stroke
Funder
National Health and Medical Research Council
Funding Amount
$2,306,367.00
Summary
Stroke is one of the top three causes of disability. Treatments that improve recovery after stroke are lacking. We reviewed the world literature and found a number of very small studies which, together, suggest that the antidepressant drug, fluoxetine, may improve the recovery in stroke patients. AFFINITY is a large trial in 1600 Australians and New Zealanders with stroke which aims to find out whether taking fluoxetine for 6 months after a stroke improves recovery compared to a placebo.
Participate-CP: Optimising Participation In Physically Active Leisure For Children With Cerebral Palsy: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,014,872.00
Summary
In Australia, 35,000 people have cerebral palsy, who compared to able-bodied peers, are less active with a greater risk of chronic, life-limiting health conditions. There are currently no effective interventions for children with cerebral palsy to increase their physical activity and participation in active leisure activities. We have promising data about a new intervention, called Participate-CP, which we will test in 80 children with cerebral palsy and compare results to usual therapy care.
Group A Streptococcal Human Challenge Study: Accelerating Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$2,018,741.00
Summary
Infection with group A streptococcus (GAS) is a major cause of morbidity and mortality worldwide, including in the Aboriginal population of Australia. Concerted efforts for vaccine development have been hampered by the absence of a suitable animal model. To address this critical knowledge gap we propose to develop a controlled human infection model of GAS infection. This model will provide a direct pathway for the future appraisal of novel GAS vaccines.
I am a practising hospital neurologist and world leader in the prevention and treatment of stroke. Our research aims to realise exciting new break-throughs for stroke sufferers by testing the effectiveness and safety of new treatments that promise to improve recovery of function of damaged brain and reduce disability after stroke, and to prevent recurrent strokes.
Novel Approaches To The Prevention And Treatment Of Chronic Heart Disease And Its Co-morbid Complications
Funder
National Health and Medical Research Council
Funding Amount
$5,793,580.00
Summary
Cardiovascular disease (CVD) and its associated additional disorders constitute major public health problems, especially given the rapidly ageing population which is increasingly affected by obesity and diabetes. This Program will explore novel therapies for the treatment of CVD and associated diseases, particularly focussing on chronic kidney disease, translating preliminary laboratory-based findings into clinical trials and then clinical and epidemiological findings into practice and policy.